Literature DB >> 6188912

Amrinone relaxes potassium-induced contracture of failing right ventricular muscle of cats.

M S Gaide, W S Fitterman, J R Wiggins, R J Myerburg, J S Cameron, A L Bassett.   

Abstract

The effects of amrinone (5.3 X 10(-4) M) on isometric contraction and K+-induced contracture force of right ventricular muscle isolated from normal cats (n = 6) and cats in right ventricular failure (RVF, n = 6), 3-14 days after partial pulmonary artery ligation, were studied. Peak isometric contractile force (Po) and maximal rate of force development (dP/dt) of RVF muscles (1.38 +/- 0.21 g/mm2; means +/- SEM, and 11 +/- 1 g/s/mm2, respectively) were significantly lower than normal muscles (2.46 +/- 0.41 g/mm2, p less than 0.025, and 24 +/- 3 g/s/mm2, p less than 0.005, respectively). Duration of contraction (DC) was significantly longer in RVF muscles (442 +/- 32 ms) than in normal muscles (361 +/- 11 ms, p less than 0.025). Times to peak twitch force (TTP) and peak K+-induced contracture force (Pc) of RVF and normal muscles were not different. Amrinone increased Po and dP/dt significantly in normal muscles (+78 +/- 24%; means +/- SEM; p less than 0.01, and +53 +/- 17%, p less than 0.025, respectively), but not RVF muscles (+11 +/- 16% and +8 +/- 19%, respectively). TTP and DC of normal muscle were unchanged by amrinone, whereas TTP was unchanged while DC was shortened (-12 +/- 3%, p less than 0.025) in RVF muscle. Amrinone relaxed Pc similarly and significantly in normal (-28 +/- 7%, p less than 0.005) and RVF (-26 +/- 4%, p less than 0.025) muscles. These results suggest that part of amrinone's salutary action in the failing heart occurs through modification of myocardial relaxation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188912     DOI: 10.1097/00005344-198303000-00028

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Alternative to the digitalis glycosides for heart failure.

Authors:  P Wilmshurst
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

2.  Side effects of amrinone therapy.

Authors:  T H LeJemtel
Journal:  Br Heart J       Date:  1983-11

3.  Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function.

Authors:  A Timmis; K Daly; D E Jewitt
Journal:  Br Heart J       Date:  1983-07

Review 4.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

5.  Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles.

Authors:  L Brown; E Erdmann
Journal:  Klin Wochenschr       Date:  1984-05-02

6.  Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.

Authors:  P T Wilmshurst; D S Thompson; S M Juul; B S Jenkins; D J Coltart; M M Webb-Peploe
Journal:  Br Heart J       Date:  1984-07

7.  Effects of intracoronary and intravenous amrinone infusions in patients with cardiac failure and patients with near normal cardiac function.

Authors:  P T Wilmshurst; D S Thompson; S M Juul; H C Dittrich; J R Dawson; J M Walker; B S Jenkins; D J Coltart; M M Webb-Peploe
Journal:  Br Heart J       Date:  1985-05

8.  Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium channels.

Authors:  P K Siegl; M L Garcia; V F King; A L Scott; G Morgan; G J Kaczorowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

9.  Interaction of amrinone with endogenous adenosine in guinea-pig atria.

Authors:  P Dorigo; I Maragno
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

Review 10.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.